Predicting Therapeutic Response and Degree of Pituitary Tumour Shrinkage during Treatment of Acromegaly with Octreotide LAR

Publisher： Karger

E-ISSN： 1663-2826|62|5|227-232

ISSN： 1663-2818

Source： Hormone Research in Paediatrics, Vol.62, Iss.5, 2004-11, pp. : 227-232

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Short- and Long-Term Efficacy of Combined Cabergoline and Octreotide Treatment in Controlling IGF-I Levels in Acromegaly

By  

Neuroendocrinology, Vol. 92, Iss. 2, 2010-08 ,pp. : 120-127

Karger

Access to resources Recommend Favorite

Pituitary Surgery for the Management of Acromegaly

By  

Hormone Research in Paediatrics, Vol. 53, Iss. 3, 2004-11 ,pp. : 71-75

Karger

Access to resources Recommend Favorite

Treatment of Acromegaly

By  

Hormone Research in Paediatrics, Vol. 62, Iss. 3, 2004-11 ,pp. : 79-92

Karger

Access to resources Recommend Favorite

Impact of Octreotide Long-Acting Release on Tumour Growth Control as a First-Line Treatment in Neuroendocrine Tumours of Pancreatic Origin

By  

Neuroendocrinology, Vol. 98, Iss. 2, 2013-08 ,pp. : 137-143

Karger

Access to resources Recommend Favorite

Pegvisomant Treatment in Acromegaly

By  

Neuroendocrinology, Vol. 103, Iss. 1, 2016-0 ,pp. : 59-65

Karger

Access to resources Recommend Favorite